摘要
越来越多乳腺癌患者选择进行术前新辅助化疗,与传统辅助化疗相比,新辅助化疗有其独特的优势。作者综述了新辅助化疗疗效,包括疗效评价系统、化疗前后的变化和化疗反应的评估。
出处
《现代医学》
2011年第2期237-240,共4页
Modern Medical Journal
参考文献21
-
1HORTOBAGYI G N.Comprehensive management of locally advanced breast cancer[J].Cancer,1990,66(6):1387-1391.
-
2FISHER E R,WANG J,BRYANT J,et al.Pathobiology of preoperative chemotherapy:findings from the National Surgical Adjuvant Breast and Bowel(NSABP) protocol B-18[J].Cancer,2002,95(4):681-695.
-
3van der HAGER J A,van da VELDE C J,JULIEN J P,et al.Preoperative chemotherapy in primary operable breast cancer:results from the European Organization for Research and Treatment of Cancer trial 10902[J].J Clin Oncol,2001,19(22):4224-4237.
-
4DAVIDSON N E,MORROW M.Sometimes a great notion-an assessment of neoadjuvant systemic therapy for breast cancer[J].J Natl Cancer Inst,2005,97:159-161.
-
5WALJEE J F,NEWMAN L A.Neoadjuvant systemic therapy and the surgical management of breast cancer[J].Surg Clin N Am,2007,87:399-415.
-
6BUZDAR A U,VALERO V,THERIAULT R,et al.Pathological complete response to chemotherapy is related to hormone receptor status.
-
7SHARKEY F E,ADDINGTON S L,FOWLER L J,et al.Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma[J].Mod Pathol,1996,9(9):893-900.
-
8ROSEN P P.Pathologic effects of therapy[J].Rosen s Breast Pathology,2001,887-897.
-
9ARENS N,BLEVL U,HILDENBRAND R.HER2/neu,p53,Ki67,and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer[J].Virchows Arch,2005,446:489-496.
-
10DOWSETT M,EBBS S R,DIXON J M,et al.Biomarker changes during neoadjuvant anastrozole,tamoxifen,or the combination:influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists[J].J Clin Oncol,2005,23:2477-2492.
同被引文献83
-
1曾谷清,康颖,高天舒,王汉群,高勇强.乳腺癌组织中P16蛋白的表达与细胞增殖的关系[J].中国现代医学杂志,2007,17(6):650-653. 被引量:5
-
2FISHER B, BRYANT J, WOLMARK N, et al. Effect of preop- erative chemotherapy on the outcome of women with operablebreast cancer[ J]. J Clin Oncol, 1998,16(8) :2672-2685.
-
3MAURIAC L, MacGROGAN G, AVRIL A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm:a uniceutre randomized trial with a 124-month median follow-up [ J]. Ann Oncol, 1999,10 ( 1 ) :47-52.
-
4BROiT P,SCHOLL S M, de la ROCHEFORDIERE A, et al. Short and long-term effects on survival in breast cancer pa- tients treated by primary chemotherapy:an updated analysis of a randomized trial [ J ]. Breast Cancer Res Treat, 1999,58 (2) : 151-156.
-
5BONADONNA G,VALAGUSSA P, BRAMBILLA C, et al. Pri- mary chemotherapy in operable breast cancer:eight-year expe- rience at the Milan Cancer Institute[ J ]. J Clin Oncol, 1998,16 (1) :93-100.
-
6van der HAGE J A, van de VELDE C J H, JULIEN J P, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treat- ment of Cancer trial 10902 [ J ]. J Clin Oneol, 2001,19 ( 22 ) : 4224-4237.
-
7BONADONNA G, VERONESI U, BRAMBILLA C, et al. Pri- mary chemotherapy to avoid mastectomy in tumors with diame- ters of three centimeters or more[ J]. J Nat Cancer Inst, 1990, 82 (19) : 1539-1545.
-
8GIANNI L, BASELGA J, EIERMANN W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer [ J ]. J Clin Oneol, 2009,27 ( 15 ) : 2474-2481.
-
9BHALLA K, HARRIS W B. Molecular and biologic determi- nants of neoadjuvant chemotherapy of locoregional breast canc- er[ C ]//Seminars in oncology. Elsevier, 1998,25 (2) : 19-24.
-
10RASTOGI P, ANDERSON S J, BEAR H D, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 [ J]. J Clin On- col,2008,26(5) :778-785.
引证文献6
-
1张才铭,袁义,聂广杰,罗仲燃.不同切口保乳术治疗乳腺癌的疗效和美容效果[J].现代医学,2013,41(7):456-459. 被引量:5
-
2李丽,张亚男,尤承忠.乳腺癌新辅助化疗的研究进展[J].东南大学学报(医学版),2013,32(6):766-771. 被引量:25
-
3高小康,孙鹤庆.新辅助化疗对乳腺癌Cerb-B2表达的影响及其临床意义[J].现代医学,2013,41(11):787-791. 被引量:4
-
4李莉,鲁英,杨晓燕,欧江华,齐新.新疆乳腺癌患者外周血中p16基因甲基化的检测意义[J].东南大学学报(医学版),2014,33(6):691-696. 被引量:2
-
5田婕丽.紫杉醇、阿霉素每周方案新辅助化疗治疗局部晚期乳腺癌与标准方案的对比研究[J].中国医药科学,2015,5(19):118-120.
-
6柴洁,卢利云.乳腺癌新辅助化疗的研究进展[J].人人健康,2016,0(18):2-2. 被引量:1
二级引证文献37
-
1郎洁,张超,宋庆文,李鹏.乳腺癌新辅助化疗前后分子生物学指标的变化及其与疗效的相关性[J].湖南师范大学学报(医学版),2020(5):54-57. 被引量:9
-
2袁领勤,江冠铭,钟慕仪,张蓉,吴丽华.残留腺体转位整形法在乳腺癌保乳手术中的应用[J].中国医学创新,2014,11(4):65-67. 被引量:2
-
3董振国,张胜利.射状切口保乳术和弧行切口保乳术治疗乳腺癌患者的临床疗效分析[J].世界最新医学信息文摘,2014,14(3):54-54. 被引量:1
-
4李振,甄林林.G-CSF在乳腺癌化疗中的研究进展[J].现代医学,2014,42(3):344-346. 被引量:1
-
5丁木莲,李峰.mTOR高选择性抑制剂AZD8055对乳腺癌多西紫杉醇耐药细胞株化疗敏感度的作用[J].医学研究杂志,2018,47(11):189-193. 被引量:3
-
6赵真,曲慧利,王新刚,柳晓义,刘晨.新辅助化疗与辅助化疗对乳癌病人生活质量影响比较[J].齐鲁医学杂志,2014,29(6):507-509. 被引量:1
-
7丁荣楣,王平,马立君,田奕,郭宏,吴娜,蔡新萍.乳腺癌术后经外周置入中心静脉导管病人血压测量部位选择的研究[J].现代医学,2014,42(10):1184-1187. 被引量:1
-
8乔伟,庄一平,马大伟,夏雷,张晋,孙磊,李旸,冯勇.乳腺癌患者乳腺外器官可疑恶性病变穿刺活检的临床意义[J].现代医学,2014,42(12):1429-1432. 被引量:1
-
9李源丰,刘磊,王安安,罗永辉.周围腺体组织瓣在乳腺癌保乳术中局部缺损修复中的应用[J].当代医学,2015,21(22):60-61. 被引量:3
-
10田传兴.保乳术结合新辅助化疗治疗乳腺癌的应用价值评析[J].中国继续医学教育,2015,7(20):82-83. 被引量:2
-
1马晓昕,唐永军.乳腺癌联合治疗的必要性[J].中国社区医师(医学专业),2010,12(7):45-45.
-
2解立武,郗彦凤.甲状腺乳头状癌中BRAF^(V600E)基因突变与临床病理特征的关系[J].山西医药杂志,2016,45(8):928-930. 被引量:3
-
3唐伟,徐弘,真船健一.基因与化疗敏感性研究[J].国外医学(肿瘤学分册),1999,26(6):325-327. 被引量:2
-
4王超奇,王岩,余大海.前列腺癌组织中OPN和Survivin表达与PSA的相关性分析[J].中国实验诊断学,2016,20(3):392-395. 被引量:5
-
5金晟娴,于洁.肿瘤化疗药物新的不良反应评价系统—CTCAE v3.0[J].儿科药学杂志,2011,17(3):53-55. 被引量:71
-
6赵洁,郭丝锦,易军.乳腺癌患者的心理状况及心理康复[J].中国妇幼健康研究,2016,27(12):1552-1554. 被引量:8
-
7吴青山,陈均.MSCT在胃癌诊断中的价值[J].中国CT和MRI杂志,2014,12(8):62-65. 被引量:17
-
8周若美,张秋生,朱绮骊,甘国维.青年人胃癌39例临床分析[J].世界华人消化杂志,1998,6(S2):371-371. 被引量:1
-
9赵日升,汪挺.生物标志物评分系统能否预测直肠癌术前放化疗后的病理完全缓解?[J].中华胃肠外科杂志,2014,17(11):1095-1095.
-
10郭艳琴,雷成功,王玉娟.乳腺浸润性导管癌的超声表现与病理组织学分级对照研究[J].山西医药杂志(上半月),2009,38(5):418-419. 被引量:6